Learn how a naturally occurring cat coronavirus is helping reveal how viral infections can linger inside the immune system.
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...
The site, which will cost about €10.0 billion ($11.7 billion) to complete, will be the third-largest of the company’s Verbund ...
A study of female U.S. service members found that getting a COVID-19 vaccine before or during pregnancy didn't raise the risk ...
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...
Nasal vaccines provide viral protection in ways injected vaccines can’t. In A Nutshell A new nasal spray vaccine fully protected ferrets from a lethal H5N1 bird flu challenge: all vaccinated animals ...
Mounting evidence from research on nematodes to mice indicate that a father's environment, such as what he eats or if he is ...
Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...
The safety of mRNA vaccines, hailed as a saviour in the covid-19 pandemic, has been called into question by the US ...
Researchers in Xi’an found city air microplastics tripled after COVID-19, with masks and pollution driving fibers into lungs, ...
On January 12, 2026, Moderna reported that it expected unaudited 2025 revenue of about $1.9 billion—slightly above prior guidance—alongside improved projected 2025 GAAP operating expenses of $5.0–$5.2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback